NCT04278872终止2 期
A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 13
- 试验地点
- 22
- 主要终点
- Mean Change in Average Daily Frequency of Moderate to Severe Vasomotor Symptoms (VMS) From Baseline to Week 4
研究概览
简要总结
This study evaluates the efficacy, safety, tolerability, and pharmacokinetics of once daily SJX-653 in postmenopausal women with moderate to severe VMS.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Signed a consent form before Screening procedures begin.
- •Be a postmenopausal female, 40 to 65 years of age (inclusive) at the Screening Visit, defined as:
- •Spontaneous amenorrhea for at least 12 months, OR
- •6 months of spontaneous amenorrhea with serum FSH levels >40 milli-International unit (mIU/mL), OR
- •6 weeks past a postsurgical bilateral oophorectomy with or without hysterectomy.
- •All postmenopausal woman (PMW) must have a serum follicle stimulating hormone (FSH) >40 mIU/mL at Screening.
- •Have an average of at least 7 moderate to severe VMS per day at Baseline. The following definitions for severity are used:
- •Mild: Sensation of heat without sweating/damping; if at night, do not wake up but later notice damp sheets or clothing.
- •Moderate: Sensation of heat with sweating/dampness, but able to continue activity; if at night, wake up because hot and/or sweating, but no action is necessary other than rearranging the bed sheets.
- •Severe: Sensation of heat with sweating causing disruption of current activity; if at night, wake up hot and sweating and need to take action (eg, removing layer of clothes, open the window, or get out of bed).
- •Have a body mass index between 18 and 35 kg/m2, inclusive.
- •For subjects 50-65 years old, have documentation (written or electronic report) of a satisfactory mammogram result at Screening within applicable intervals stated in local breast cancer screening guidelines. Subjects 40-49 years old require a mammogram within the same intervals.
- •Have documentation (written or electronic report) of a normal Pap smear (or equivalent cervical cytology) ) in combination with Human Papilloma virus (HPV) testing, or a Pap smear of no clinical significance in the opinion of the Investigator, at Screening within applicable intervals stated in local cervical cancer prevention guidelines.
- •Have an endometrial thickness ≤4 mm by transvaginal ultrasound at Screening.
- •Be willing to undergo an endometrial biopsy if they have unexplained bleeding during the study or endometrial thickness >4 mm at the EOT visit. An endometrial biopsy is not required for subjects who have had a partial (supracervical) or full hysterectomy.
排除标准
- •Have clinically significant history or evidence of poorly controlled cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s) as determined by the Investigator or have any medical condition that requires chronic medication and that in the Investigator's opinion, would make subjects unsuitable for participation in the study.
- •Have manifest or suspected active COVID-19 infection. Have tested positive for presence of SARS-CoV-2 based on a RT-PCR or other validated test; or have clinical symptoms suggestive of COVID-19 infection; or have to comply with quarantine requirements per local Public Health directive.
- •Have a history of diagnosis of major depressive disorder in the 3 years prior to Screening, or are on any antidepressant, anxiolytic or antipsychotic treatment. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) treatment for mild depression and/or mild anxiety is allowed provided medication is stable and well-tolerated in the 3 months prior to the Screening Visit and does not change during study participation.
- •Have a history of suicide ideation or attempt in the past 3 years.
- •Have a history of a sleep disorder other than insomnia due to VMS (eg, narcolepsy, sleep apnea, restless leg syndrome).
- •Have clinical or biochemical evidence of active hepatitis or other significant hepatic or biliary disease (eg, chronic hepatitis, cirrhosis, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, or hereditary liver disease).
- •Have any abnormal liver function tests at Screening or an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 (CKD-EPI 2009 calculation; Levey et al 2009).
- •Have tested positive for human immunodeficiency virus, hepatitis B, C or E at Screening.
- •Have any gastrointestinal, liver, kidney or other disorder that would significantly interfere with the absorption, distribution, metabolism, or excretion (ADME) of drugs in the opinion of the Investigator.
- •Have a history of alcohol abuse or a history of substance abuse.
- •Smoking >10 cigarettes per day.
- •Regularly working night shifts.
- •Systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg, based on the median of a total of 4 to 6 readings, from 2 to 3 readings taken on 2 different occasions.
- •Have clinically significant abnormal ECG or QT interval prolongation (corrected for heart rate using Fridericia formula [QTcF] prolongation >470 ms) at Screening.
- •Have a history of endometrial hyperplasia or uterine/endometrial cancer.
- •Have current unexplained uterine bleeding.
- •Have a history of cancer prior to Screening (other than local, treated basal cell or squamous cell carcinoma).
- •Have any significant illness requiring hospitalization or emergency treatment within 4 weeks prior to the Screening Visit or during the Screening or Run-in Periods, and as determined by the Investigator.
- •Are pregnant or lactating.
- •Have used hormonal treatments within defined periods of time prior to the start of the Run-in Period. Washout times dependent on treatment.
- •Are taking any nonhormonal medication for treatment of VMS in the 8-week period prior to the start of the Run-in Period.
- •Have used herbal supplements or over-the-counter (OTC) medications for treatment of VMS 8 weeks prior to the start of the Run in Period. Any other herbal supplements or OTC supplements that could interfere with the study objectives require a 28-day wash-out period prior to the start of the Run-in Period.
- •Are taking any antiestrogens, selective estrogen receptor modulators, or aromatase inhibitors.
- •Are taking any antigonadotropin medication.
研究组 & 干预措施
Placebo
Placebo Comparator
Participants will receive placebo
干预措施: Placebo (Drug)
SJX-653
Experimental
Participants will receive SJX-653
干预措施: SJX-653 (Drug)
结局指标
主要结局
Mean Change in Average Daily Frequency of Moderate to Severe Vasomotor Symptoms (VMS) From Baseline to Week 4
时间窗: Baseline to Week 4
Moderate to severe vasomotor symptoms collected daily by e-diary
次要结局
- Mean Change in the Severity of Moderate to Severe VMS From Baseline to Week 4(Baseline to Week 4)
- Mean Change and Percent Change of Parameters of VMS Frequency and Severity by Study Week(Baseline up to Week 6)
研究者
研究点 (22)
Loading locations...
相似试验
已完成
1 期
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult ParticipantsHealthyNCT02418559Janssen Infectious Diseases BVBA24
终止
1 期
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-61803534 and to Evaluate the Effect of JNJ-61803534 on the Pharmacokinetics of Midazolam in Healthy ParticipantsHealthyNCT03139500Janssen Research & Development, LLC47
已完成
1 期
A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's DiseaseAlzheimer DiseaseNCT03375697Janssen Research & Development, LLC72
已完成
1 期
A Study of JNJ-63733657 in Healthy Japanese ParticipantsHealthyNCT03689153Janssen Pharmaceutical K.K.24
已完成
1 期
A Study of JNJ-73763989 in Healthy Japanese Adult ParticipantsHealthyNCT04002752Janssen Sciences Ireland UC25